Screener / SEC EDGAR /CIK 0001777921 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Technology · Software

AvePoint, Inc. AVPT

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of AVPT's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter Sep 4, 2024
Questions asked 61 each answered in the company's own letter
No closing letter 3 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 9 UPLOAD
  2. 2. Questions in them 61 numbered comments
  3. 3. Company replies 13 CORRESP
  4. 4. Reviews closed 1 of 4 closing letter

Half the closed reviews took 22 days or less from the first letter to the closing letter.

Schedule TO-I

2024-09-04 to 2024-09-09 · 7 questions · 1 letter from the SEC, 1 from the company
No closing letter
Schedule TO-I filed August 27, 2024; Offer Letter · General
SEC asked (1)
Please ensure on future filings that the EDGAR tag "SC 13E-3/A" is associated with the filing, in addition to the EDGAR tag "SC TO-I/A."
AVPT answered
The Company respectfully acknowledges the Staff’s comment and advises the Staff that the Company will ensure on future filings that the EDGAR tag “SC 13E-3/A” is associated with each filing, in addition to the EDGAR tag “SC TO-I/A.”
Read in the reply
Schedule TO-I filed August 27, 2024; Offer Letter · General
SEC asked (2)
Refer to your disclosure of “[a]lternatives: None” in Item 7(b) of the Schedule TO-I. Refer also to disclosure on page three of the Offer Letter that “[i]n evaluating the Transaction, the Company considered conducting an exchange offer for the Warrants as an alternative in which the Warrants would be exchanged for shares of Common Stock.” Given this apparent discrepancy, please revise or advise.
AVPT answered
The Company respectfully acknowledges the Staff’s comment and has amended and restated “(b). Alternatives” of “Item 7. Purposes, Alternatives, Reasons and Effects” of the Amended Tender Offer Statement accordingly.
Read in the reply
Schedule TO-I filed August 27, 2024; Offer Letter · General
SEC asked (3)
Disclosure in Item 9(c) states “[n]ot applicable.” Please revise and make the statements required by Item 1015(c) of Regulation M-A in the disclosure document.
AVPT answered
The Company respectfully acknowledges the Staff’s comment and has amended and restated “(c). Availability of documents” of “Item 9. Reports, Opinions, Appraisals and Negotiations” of the Amended Tender Offer Statement accordingly.
Read in the reply
Schedule TO-I filed August 27, 2024; Offer Letter · General
SEC asked (4)
Please provide the information required by Item 1003(c)(5) of Regulation M-A.
AVPT answered
The Company respectfully acknowledges the Staff’s comment and has amended Schedule I to the Offer to Purchase accordingly.
Read in the reply
Summary Term Sheet, page 1
SEC asked (5)
We note the following disclosure on pages 3 and 26: "The foregoing conditions are solely for our benefit, and we may assert one or more of the conditions regardless of the circumstances giving rise to any such conditions." All offer conditions must be objective and outside the control of the offeror in order to avoid illusory offer concerns under Regulation 14E.
Rest of the question

Please revise the language relating to the circumstances that may "trigger" an offer condition to avoid the implication that they may be within the Company's control. See Question 101.02 of the Division of Corporation Finance's "Tender Offer Rules and Schedules" Compliance and Disclosure Interpretations.

AVPT answered
The Company respectfully acknowledges the Staff’s comment and has amended the disclosure on page 3 under the “Summary Term Sheet” of the Offer to Purchase and page 26 under “The Offer and Consent Solicitation, Section 10. Conditions; Termination; Waivers; Extensions; Amendments” of the Offer to Purchase” of the Offer to Purchase accordingly.
Read in the reply
Effects of the Transaction on the Market for the Warrants, page 5
SEC asked (6)
We note your disclosure on page six that “[t]he Offer Purchase Price was determined following negotiations with parties holding more than a majority of the outstanding Warrants.” Describe such negotiations, including who initiated such negotiations. Refer to Item 1005(c)(2) of Regulation M-A, including the instruction thereto.
AVPT answered
The Company respectfully acknowledges the Staff’s comment and has amended the disclosure on page 1 under “Special Factors, Section 2. Fairness of the Transaction (Offer, Consent Solicitation and Redemption)” and page 6 under “Special Factors, Section 4. Effects of the Transaction on the Market for the Warrants” of the Offer to Purchase accordingly.
Read in the reply
Source and Amount of Funds; Fees and Expenses, page 21
SEC asked (7)
Refer to disclosure on page 21 that you “estimate that the total amount of cash required to complete the Offer and Consent Solicitation, including the payment of any fees, expenses and other related amounts incurred in connection with the Offer and Consent Solicitation will be approximately $1,324,000 million” (emphasis added), which appears to be a typographical error.
Rest of the question

In addition, $1,324,000 appears to solely reflect the fees, expenses and does not include the amount required to purchase all of the outstanding Warrants. Please revise.

AVPT answered
The Company respectfully acknowledges the Staff’s comment and has amended the disclosure on page 21 under “The Offer and Consent Solicitation, Section 6. Source and Amount of Funds; Fees and Expenses” of the Offer to Purchase accordingly.

*****

Should any member of the Staff have any questions or comments concerning this filing or the materials submitted herewith or desire any further information in respect of this filing or the materials submitted herewith, please do not hesitate to contact me at (650) 843-5059 or Justin A. Kisner at (650) 843-5080.
Read in the reply

Form 10-K for the Fiscal Year ended December 31, 2022

2023-05-23 to 2023-06-14 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2023-06-14
Controls
Item 9A. Controls and Procedures, page 79
SEC asked
Please revise to include Management’s annual report on internal control over financial reporting. Please ensure that your disclosure complies with Item 308(a) of Regulation S- X including disclosing the framework used by management. Refer to the Instructions to Item 308 of Regulation S-K.
AVPT answered
We acknowledge the Staff’s comment and will amend the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Form 10-K/A”) to include management’s annual report on internal control over financial reporting. The following disclosures will be addressed in such report on internal control over financial reporting included in the Form 10-K/A:

● management’s responsibility for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended) for the
Rest of the answer

Company;

a statement identifying the Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) as the framework used by management to evaluate the effectiveness of the Company’s internal control over financial reporting;

management’s assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2022, including a statement as to whether or not internal control over financial reporting was effective and a discussion of any material weaknesses in the Company’s internal control over financial reporting identified by management; and a statement that the Company’s Annual Report on Form 10-K does not include an attestation report of the Company’s registered public accounting firm regarding internal controls over financial reporting, because the Company was not subject to such attestation as an “emerging growth company” as defined by Rule 405 of the Securities Act of 1933, as amended, and Rule 12b-2 of the Securities Exchange Act of 1934, as amended.

Attached hereto as Exhibit A is the Company’s proposed revised “Item 9A. Controls and Procedures” to be included in the Form 10-K/A.

We hope that the foregoing has been responsive to the Staff’s comment. If you have any questions related to this letter, please contact the undersigned at 804-314-5903.

Read in the reply
In its next report

First report after the company's reply of Jun 8, 2023: 10-Q filed Aug 9, 2023 ↗, against the 10-Q filed May 10, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2023-06-14

Form S-4

2021-03-03 to 2021-08-05 · 50 questions · 5 letters from the SEC, 7 from the company
No closing letter
RevenueAcquisitionsResults discussion (MD&A)SegmentsCritical estimatesRisk factorsIncome taxesLiquidity and cash
SEC letter of Mar 3, 2021 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Cover Page
SEC asked (1)
You disclose how the cash consideration will be calculated and total merger consideration will be determined. We encourage you to provide context to this discussion by explaining the reasons for structuring the consideration in this manner. For example, explain why you are offering both cash and stock and why the total amount of cash that can be elected has been capped.
Rest of the question

Furthermore, please provide an estimated range of the cash consideration based upon no redemptions and the maximum amount of redemptions that allow the company to meet the minimum proceeds condition of $300 million. Finally, provide a cross-reference to disclosure that provides examples of the amount of cash and Apex shares an AvePoint stockholder could receive per share under different scenarios.

AVPT answered

No reply letter found.

Cover Page
SEC asked (2)
On page 84, you state that each share of AvePoint's common stock, convertible preferred stock and preferred stock will be converted into approximately 8.6816 shares of Apex common stock based on the determined exchange ratio. Please disclose and describe the estimated exchange ratio on the cover page.
AVPT answered

No reply letter found.

Questions and Answers about the Business Combination · If I hold Apex Warrants, can I exercise redemption rights with respect to my warrants?, page xvi
SEC asked (3)
Clarify that although holders of Apex warrants do not have redemption rights with respect to the Apex warrants, if they choose to redeem their Apex shares, they may still exercise their warrants if the merger is consummated. What equity stake will current Apex stockholders and AvePoint stockholders have in the Combined Company after the Closing?, page xvii
AVPT answered

No reply letter found.

Questions and Answers about the Business Combination · If I hold Apex Warrants, can I exercise redemption rights with respect to my warrants?, page xvi
SEC asked (4)
We note that you disclose the equity stake of certain stockholder groups assuming no redemption. Please revise to also disclose the equity stake of these groups assuming maximum redemption.
AVPT answered

No reply letter found.

What vote is required to approve the proposals... ?, page xviii
SEC asked (5)
On page 64, you disclose that Apex's Sponsor, executive officers, directors and director nominees have agreed to vote in favor of the business combination. Please revise this Q&A and elsewhere to disclose the percentage of Apex shares that are subject to an agreement to vote in favor of the business combination.
Rest of the question

Additionally, since the business combination proposal requires only the affirmative vote of the majority of the votes cast by Apex stockholders, also disclose the percentage of remaining shares needed to vote for the business combination proposal if only a quorum of Apex shares are present.

AVPT answered

No reply letter found.

The Background of the Business Combination, page 94
SEC asked (6)
On page 98, you disclose that Apex and AvePoint, following input from their financial advisors, discussed valuation metrics with regard to the potential business combination and agreed to the previously proposed equity valuation of $2.0 billion.
Rest of the question

You also note that the Apex board discussed in detail an analysis of the valuation of AvePoint and that William Blair discussed its financial analysis of the transaction consideration, including an overview of key valuation metrics and relevant public company comparables for AvePoint. Please revise to further explain how the Apex board determined the $2.0 billion valuation of AvePoint. Disclose the analyses the board considered, including any underlying material projections, assumptions or estimates.

AVPT answered

No reply letter found.

Material U.S. Federal Income Tax Considerations of the Redemption Rights, page 119
SEC asked (7)
You state that this section is a discussion of certain material U.S. federal income tax considerations for holders of Public Shares electing to have their shares redeemed for cash upon the closing of the Business Combination. Please revise to discuss the material tax consequences of the business combination to each company's shareholders and the company.
Rest of the question

In this regard, the merger agreement indicates that the parties intend for the merger and related transactions to be tax free under Section 368(a) of the Internal Revenue Code. If you believe the business combination will be tax free, please disclose an opinion of counsel that supports this conclusion. Furthermore, indicate that the receipt of a tax opinion as to the tax free nature of the transaction is not a condition to the merger. Also, provide summary and risk factor disclosure to address the tax consequences. Refer to Item 601(b)(8) of Regulation S-K and our Staff Legal Bulletin No. 19.

AVPT answered

No reply letter found.

Proposal No. 5 -- The Nasdaq Proposal, page 146
SEC asked (8)
Unless the PIPE financing closing condition cannot be waived, shareholders should be afforded the opportunity to vote separately on the issuance of shares in connection with the merger and the PIPE financing. Please separate each into its own proposal for shareholder approval, or clarify that the merger will not occur unless the PIPE financing is consummated.
AVPT answered

No reply letter found.

Information about AvePoint · Strategic Relationships, page 175
SEC asked (9)
You state here that Microsoft is AvePoint's most important strategic partner. Elsewhere you state that AvePoint's success depends on its partnership with Microsoft and note that Microsoft co-sells and co-markets AvePoint's products and services.
Rest of the question

Please revise to disclose the material terms of AvePoint's material agreements with Microsoft and consider whether any such agreements should be filed pursuant to Item 601(b)(10) of Regulation S-K.

AVPT answered

No reply letter found.

Operations · Key Business Metrics, page 194
SEC asked (10)
You disclose and define certain key business metrics. Please revise to discuss why management views these metrics as key business metrics, how management uses these metrics to manage the business and the reasons for material changes to these metrics between periods.
AVPT answered

No reply letter found.

Operations · Key Business Metrics, page 194
SEC asked (11)
Tell us your consideration of disclosing your number of customers categorized between small-and-medium business, mid-market, and large enterprise customer segments in this section. In this regard, we note you provide partial highlights of these categories in your filing, such as on pages 27, 31, 159, 160, and 174.
AVPT answered

No reply letter found.

Annual Recurring Revenue, page 194
SEC asked (12)
We note your definition of annual recurring revenue. Please revise to explain how this metric captures recurring revenue and discuss any limitations of this metric.
AVPT answered

No reply letter found.

Comparison of Nine Months Ended September 30, 2020 and September 30, 2019 · Revenue, page 199
SEC asked (13)
Your disclosure on page 196 indicates that the Subscription Revenue line item includes revenue from sale of on-premise termed licenses and cloud-based (SaaS) versions of your software and related customer support. Please revise to disclose disaggregated revenue amounts for on-premise termed licenses and SaaS software.
Rest of the question

In addition, revise to disclose the amount of revenue recognized from the sale of perpetual on-premise licenses. In this regard, your discussion should analyze revenue recognized from your offerings as disclosed on page F-12 and clearly discuss their continuing contribution to revenue. Please expand your discussion to identify and quantify the material factors in each of your revenue offerings.

AVPT answered

No reply letter found.

Comparison of Nine Months Ended September 30, 2020 and September 30, 2019 · Revenue, page 199
SEC asked (14)
We note you provide a disaggregation of revenue by geographic region in your results of operations, but do not provide any further commentary. Please expand your disclosure to identify and quantify the material factors for the changes in revenue in your geographic regions. Refer to Section III.B of SEC Release No. 33-8350. Similar concerns apply to your disclosures on page 202.
AVPT answered

No reply letter found.

Comparison of Nine Months Ended September 30, 2020 and September 30, 2019 · Revenue, page 199
SEC asked (15)
Please separately discuss and analyze revenues recognized from your managed services offering. Describe the nature of this service and indicate how this service relates to your other offerings.
AVPT answered

No reply letter found.

Cost of Revenue, Gross Profit, and Gross Margin, page 200
SEC asked (16)
We note you break-out your cost of revenues by revenue components in your consolidated statements of operations on page F-3. Similarly, please revise your discussion to discuss the changes in your cost of revenue by revenue component rather than in total. Similar concerns apply to your disclosures on page 202.
AVPT answered

No reply letter found.

General and Administrative, page 201
SEC asked (17)
As noted in footnote 1 on page 199, tell us and disclose why all of your stock-based compensation has been allocated to General and administrative expenses rather than to other line items as well. We refer you to SAB Topic 14.F. The expense related to sharebased payment arrangements should be presented in the same line or lines as cash compensation paid to the same employees.
AVPT answered

No reply letter found.

Emerging Growth Company Accounting Election, page 213
SEC asked (18)
You disclose here that the combined company "expects to continue to take advantage of the benefits of the extended transition period" for complying with new or revised accounting standards. Please revise to clearly indicate, if true, that you have elected to take advantage of this extended transition period and also disclose that your financial statements may not be comparable to companies that comply with public
Rest of the question

company effective dates. Additionally, ensure that your registration statement cover page includes the check box related to this election.

AVPT answered

No reply letter found.

Description of Apex's Securities · Exclusive Forum Selection, page 248
SEC asked (19)
You disclose here that the bylaws that will be in effect upon the consummation of this business combination will contain certain exclusive forum provisions. In a risk factor on page 63, you note that these provisions will appear in your proposed certificate of incorporation that will be in effect following this business combination. Please reconcile this apparent discrepancy.
AVPT answered

No reply letter found.

Consolidated Statements of Operations, page F-3
SEC asked (20)
Your Statement of Operations includes the subtotal, Gross Margin. Please tell us and disclose if you include depreciation or amortization in cost of revenue. If you do not include depreciation or amortization in cost of revenue, please revise your presentation if material to comply with SAB Topic 11.B.
AVPT answered

No reply letter found.

Note 2. Summary of Significant Accounting Policies · Basis of Presentation, page F-9
SEC asked (21)
Please clarify why deferred revenue decreased upon adoption of ASC 606. Tell us and disclose the revenue offering and the application difference between ASC 605 and 606 that caused this difference.
AVPT answered

No reply letter found.

Notes to Consolidated Financial Statements, page F-9
SEC asked (22)
We note your disclosure of related party transactions on page 189. Please provide footnote disclosure of these related party transactions. Refer to ASC 850-10-50.
AVPT answered

No reply letter found.

Notes to Consolidated Financial Statements, page F-9
SEC asked (23)
Your disclosure on page 23 indicates that you reduced your global workforce by approximately 10% during the first half of 2020. Please provide footnote disclosure to disclose the applicable costs related to this reduction. Refer to ASC 420-10-50. In addition, consider presenting restructuring charges on a separate line item if material. Refer to SAB Topic 5P(1).
AVPT answered

No reply letter found.

Notes to Consolidated Financial Statements, page F-9
SEC asked (24)
We note your disclosure of your 401(k) plan on page 187. Please disclose this 401(k) plan in your footnotes and any Company contributions. Refer to ASC 715-70-50-1.
AVPT answered

No reply letter found.

Deferred Sales Commissions, page F-11
SEC asked (25)
Please clarify whether the renewal commissions are commensurate with the initial commission. In paragraph BC309 of ASU 2014-09, the Boards indicated that amortizing capitalized commissions over a period that is longer than the initial contract term is not appropriate if an entity pays a commission on renewing a contract that is commensurate with the commission paid when obtaining the original contract.
Rest of the question

In addition, please explain why the renewal commission is being amortized over a period of benefit instead of the renewal term.

AVPT answered

No reply letter found.

Revenue Recognition, page F-12
SEC asked (26)
Your disclosure on page F-14 indicates that your on-premise perpetual licenses have not historically been sold on a standalone basis. Please clarify if you do sell your on-premises termed licenses on a standalone basis. That is, the term license appears to always be bundled with term maintenance.
AVPT answered

No reply letter found.

Revenue Recognition, page F-12
SEC asked (27)
Please tell us your consideration of providing disclosure here of disaggregated of revenue by geographic region noted on pages 200 and 202. In addition, tell us your consideration of providing your disaggregated disclosure of revenue by Industries. In this regard, we note your graphic presentation of Customers Across Diversified Industries on page 174. Refer to ASC 606-10-55-91(b) and 91(c).
Rest of the question

In addition, please revise to separately disclose the amount of revenue recognized at a point in time and over time. Refer to ASC 606-1055-91(f).

AVPT answered

No reply letter found.

Revenue Recognition, page F-12
SEC asked (28)
You disclose that you recognize "software revenue through all indirect sales channels on a sell-through model." Please clarify whether the indirect sales channel is your customer under ASC 606-10. Tell us when your product is delivered in these circumstances. Explain how your channel partner is compensated. Revenue should be recognized when control of the products are transferred.
Rest of the question

Refer to ASC 606-10-25-25 and 25-30. Note 14. Segment information, page F-34

AVPT answered

No reply letter found.

Revenue Recognition, page F-12
SEC asked (29)
Please expand your disclosure to present revenue attributed to customers in the United States as well as disclose long-lived assets by geographic location. Refer to ASC 280-1050-41.
AVPT answered

No reply letter found.

Exhibits
SEC asked (30)
Please file the form of proxy with your next amendment.
AVPT answered

No reply letter found.

General
SEC asked (31)
Please revise to add diagrams depicting the pre-combination organizational structure of both Apex and AvePoint and the post-combination organizational structure of the combined company. Ensure that these diagrams, as applicable, clearly identify ownership percentages of the different security holder groups, such as the Sponsor, Apex public stockholders, the AvePoint equityholders and the PIPE subscribers under both
Rest of the question

no and maximum redemption scenarios.

AVPT answered

No reply letter found.

The Background of the Business Combination, page 96
SEC asked (1)
We note the revisions made on page 100 in response to prior comment 6. We also note the AvePoint projected financial information provided on page 102. Please further revise to describe both William Blair's financial analysis and the comparable analysis performed by the AvePoint board.
AVPT answered
In response to the Staff’s comment, the Company has revised its disclosure on page 100 of the Revised Registration

Statement.
Read in the reply
Customers Across Diversified Industries, page 181
SEC asked (2)
Your response to prior comment 27 indicates that this graph includes examples of customers and the industries that you serve or have served. Please provide a note to this graph noting that, if true, not all of the identified companies are current customers.
AVPT answered
In response to the Staff’s comment, the Company has revised its disclosure on page 181 of the Revised Registration Statement to replace the graphic at the top of the page with a graphic that provides a representative population of AvePoint’s current customers across diversified industries.
Read in the reply
AvePoint Management and Discussion of Financial Condition and Results of Operations · Key Business Metrics, page 202
SEC asked (3)
We have reviewed your response to prior comment 11 that you believe a more accurate evaluation of your business is through representation of total customer count. Please tell us your consideration of including your total customer count for each period presented.
AVPT answered
In response to the Staff’s comment, the Company notes that AvePoint did consider disclosing total customer count for the periods presented but AvePoint believes that the best customer-centric metric representing the health of AvePoint’s business is through the number of AvePoint customers that have an ARR exceeding $100,000. As such, the

Company has disclosed this figure as one of AvePoint’s key business metrics within the section titled “AvePoint Management’s Discussion and Analysis of Financial Condition and Results of Operations” on pages 202 and 203 of the

Revised Registration Statement.
Read in the reply
AvePoint Management and Discussion of Financial Condition and Results of Operations · Key Business Metrics, page 202
SEC asked (4)
We note your response to prior comment 12, including your statement that ARR is not a forecast and the active contracts at the end of the reporting period used in calculating ARR may or may not be extended or renewed by AvePoint's customers.
Rest of the question

Please consider adding disclosure that balances this metric in light of the fact that it prospectively annualizes subscription revenue from customers that sign contracts for less than one quarter in duration. In this regard, consider separately disclosing your Total Core ARR and your Total MRR, and providing an additional metric concerning your customer churn or ability to retain customers with contracts that are less than one quarter in duration.

AVPT answered
In response to the Staff’s comment, the Company has revised its disclosures on page 202 of the Revised Registration Statement to further clarify that (a) while AvePoint’s does prospectively annualize its subscription revenue, AvePoint’s MRR is attributable to its Channel business and that (b) AvePoint’s customer contracts used in calculating MRR may not be extended or renewed by AvePoint’s customers.

Given the newly created nature of AvePoint’s channel business line (and thus the short history of meaningful AvePoint MRR data) and its growth, the Company does not believe that sufficient data
Rest of the answer

exists related to AvePoint’s customer churn for such data to be a meaningful metric. As such, the Company notes that AvePoint does not manage its Channel business line using this customer churn metric nor does AvePoint actively track it. On a going forward basis, AvePoint will endeavor to disclose such metrics as and when AvePoint achieves a material enough data set such that those metrics will be indicative of

AvePoint’s overall growth.

Read in the reply
Comparison of Years Ended December 31, 2020 and December 31, 2019 · Revenue, page 207
SEC asked (5)
We have reviewed your response and expanded disclosure in response to prior comment 13. We repeat our prior comment to disclose disaggregated revenue amounts for onpremise termed licenses and SaaS software. In addition, revise to disclose the amount of revenue recognized from the sale of perpetual on-premise licenses.
Rest of the question

Please expand your discussion to identify and quantify the material factors in each of your revenue offerings. For example, identify and quantify the change in each revenue stream by new customer and existing customers.

AVPT answered
In response to the Staff’s comment, the Company has revised its disclosures on pages 207, 208, 210, and 211 of the

Revised Registration Statement to disclose AvePoint’s disaggregated revenue amounts for on-premises termed licenses and SaaS software, to disclose the amount of AvePoint’s revenue recognized from the sale of perpetual on-premises licenses, and to expand on the material factors in each of AvePoint’s revenue offerings.
Read in the reply
Comparison of Years Ended December 31, 2020 and December 31, 2019 · Revenue, page 207
SEC asked (6)
We have reviewed your response and expanded disclosure in response to prior comment 14. Your expanded disclosure that the geographic composition of revenues did not meaningfully shift is unclear to us. For example, each of your geographic regions experienced significant growth in 2020 compared to 2019, such as your North America region that experienced revenue growth of 39.5% for the year ended December 31, 2020
Rest of the question

compared to the year ended December 31, 2019. In addition, your EMEA revenue increased 29.0% for the year ended December 31, 2019 compared to the year ended December 31, 2018. As such, we repeat our prior comment 14 to expand your disclosure to identify and quantify the material factors for the changes in revenue in your geographic regions. Refer to Section III.B of SEC Release No. 33-8350.

AVPT answered
In response to the

Staff’s comment, the Company has revised its disclosures on pages 208 and 211 of the Revised Registration Statement to provide additional context as to the factors driving changes in AvePoint’s revenue in different geographic regions.
Read in the reply
Cash Flows · Operating Activities, page 215
SEC asked (7)
We note that your discussion of cash flows from operating activities is essentially a recitation of the reconciling items identified on the face of the statement of cash flows. This does not appear to contribute substantively to an understanding of your cash flows. Rather, it repeats items that are readily determinable from the financial statements.
Rest of the question

When preparing the discussion and analysis of operating cash flows, you should address material changes in the underlying drivers that affect these cash flows. These disclosures should also include a discussion of the underlying reasons for changes in working capital items that affect operating cash flows. Refer to Section IV.B.1 of SEC Release No. 33-8350.

AVPT answered
In response to the Staff’s comment, the Company has revised its disclosure on page 215 of the Revised Registration

Statement to provide additional context as to the factors driving changes in AvePoint’s operating cash flows.
Read in the reply
Consolidated Statements of Operations, page F-3
SEC asked (8)
We note your response to prior comment 20. Please explain and disclose in greater detail how you concluded that your allocation of depreciation to amortization to cost of revenues would be less than 1% of total cost of revenue.
AVPT answered
In response to the Staff’s comment, the Company has revised its disclosure on pages F-11 and F-21 of the Revised

Registration Statement. The Company notes that AvePoint utilized its organizational headcount to estimate the amount of depreciation and amortization that would be allocated to AvePoint’s cost of revenue.
Rest of the answer

Specifically, the Company advises that

AvePoint has calculated the ratio of its organizational headcount directly associated with AvePoint’s cost of revenue to AvePoint’s total headcount and ultimately calculated an estimated depreciation and amortization allocation amount of approximately $0.4 million or 1% of cost of revenue for all years presented.

Read in the reply
Note 2. Summary of Significant Accounting Policies · Basis of Presentation, page F-9
SEC asked (9)
We note your response to prior comment 21 and your expanded disclosure. Please expand upon your disclosure, that, "deferred revenue decreased as a result of recognition of revenue related to certain subscription offerings, which under ASC 605 were generally recognized over the life of the related customer agreements, but under ASC 606 are recognized at a point in time upon delivery of an on-premises termed license."
Rest of the question

In this regard, it is unclear if you are referring to SaaS arrangements or licensing arrangements. Refer to ASC 606-10-55-54(a) and 985-20-15-5.

AVPT answered
In response to the Staff’s comment, the Company notes that its intention was to refer to AvePoint’s licensing arrangements. The Company has revised its disclosures on pages F-9]and F-10 of the Revised Registration Statement to clarify that the decrease in AvePoint’s deferred revenue was specifically attributable to AvePoint’s on-premises termed licenses.
Read in the reply
Revenue Recognition, page F-12
SEC asked (10)
We note your response to prior comment 26. It is unclear how you have responded to our comment as your revised disclosure does not appear to disclose that you do not sell your on-premises termed licenses on a standalone basis. Please clarify or revise accordingly.
AVPT answered
In response to the Staff’s comment, the Company has revised its disclosures on pages F-14 and F-15 of the Revised Registration Statement to clarify that AvePoint does not sell its on-premises termed licenses on a standalone basis.

* *

*

If you have additional questions or require any additional information with respect to the

Revised Registration Statement or this letter, please do not hesitate to contact me at [email protected] or (650) 463-4662.
Read in the reply
SEC letter of Apr 16, 2021 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
The Background of the Business Combination, page 96
SEC asked (1)
We note the revisions made in response to prior comment 1. Please revise to disclose the various multiples calculated for both AvePoint and the comparable companies, including a discussion of how AvePoint's enterprise value was calculated for the purpose of these analyses.
AVPT answered

No reply letter found.

Comparison of Years Ended December 31, 2020 and December 31, 2019 · Revenue, page 207
SEC asked (2)
We note your expanded disclosures in response to prior comment 5. Please remove your "Total Subscription" subtotal line item. In this regard, we note On-premises/hybrid software licenses are not subscriptions. Refer to ASC 606-10-55-54(a). Similarly, revise your discussion of revenue on pages 208 and 211 to reflect the removal of the Total Subscription subtotal.
AVPT answered

No reply letter found.

Critical Accounting Policies and Estimates · Equity-Based Compensation, page 222
SEC asked (3)
Please provide us with a breakdown of all equity awards granted to date in fiscal 2020 and leading up to the filing of the Form S-4, including the fair value of the underlying common stock used to value such awards as determined by your board of directors.
Rest of the question

To the extent there were any significant fluctuations in the fair values from period-to-period, please describe for us the factors that contributed to these fluctuations, including any intervening events within the Company or changes in your valuation assumptions or methodology. Compare the most recent valuations for options granted to the fair value of the shares of commons stock as determined by the exchange ratio described in the Business Combination Agreement.

AVPT answered

No reply letter found.

General
SEC asked (4)
You announced that AvePoint’s Board of Directors has authorized a share purchase program pursuant to which AvePoint may purchase up to $20.0 million of Apex Technology Acquisition Corporation common stock until the date on which Apex’s S-4 Registration Statement is declared effective.
Rest of the question

Please provide us with the details of the share purchase program and an analysis of how such purchases would comply with the requirements of Rule 14e-5 under the Exchange Act. Ensure your analysis includes a discussion of whether you are a "covered person" pursuant to Rule 14e-5(c)(3)(iv).

AVPT answered

No reply letter found.

The Background of the Business Combination, page 96
SEC asked (1)
We note the revisions made in response to prior comment 1. Please revise to disclose the various multiples calculated for both AvePoint and the comparable companies, including a discussion of how AvePoint's enterprise value was calculated for the purpose of these analyses.
AVPT answered

No numbered answer found in the reply. Read the reply ↗

Comparison of Years Ended December 31, 2020 and December 31, 2019 · Revenue, page 207
SEC asked (2)
We note your expanded disclosures in response to prior comment 5. Please remove your "Total Subscription" subtotal line item. In this regard, we note On-premises/hybrid software licenses are not subscriptions. Refer to ASC 606-10-55-54(a). Similarly, revise your discussion of revenue on pages 208 and 211 to reflect the removal of the Total Subscription subtotal.
AVPT answered

No numbered answer found in the reply. Read the reply ↗

Critical Accounting Policies and Estimates · Equity-Based Compensation, page 222
SEC asked (3)
Please provide us with a breakdown of all equity awards granted to date in fiscal 2020 and leading up to the filing of the Form S-4, including the fair value of the underlying common stock used to value such awards as determined by your board of directors.
Rest of the question

To the extent there were any significant fluctuations in the fair values from period-to-period, please describe for us the factors that contributed to these fluctuations, including any intervening events within the Company or changes in your valuation assumptions or methodology. Compare the most recent valuations for options granted to the fair value of the shares of commons stock as determined by the exchange ratio described in the Business Combination Agreement.

AVPT answered
Historical Fair Value Determination and Methodology

As stated in the Registration Statement, stock-based compensation expense related to stock options granted to employees is measured at the date of grant based on the fair value of the award. The Registration Statement describes AvePoint’s use of the Black-Scholes option-pricing model for these purposes and describes and quantifies the significant assumptions used.

AvePoint’s Board of

Directors (the “AvePoint Board”) intended all options granted to be exercisable at a price per share no less than the per share fair value of the common
Rest of the answer

stock of AvePoint underlying those options on the date of

Page grant. The estimated fair value of the voting common stock underlying stock options was determined at each grant date by the AvePoint Board and was supported by periodic independent third-party valuations. The valuations of the voting common stock were determined in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity

Securities Issued as Compensation as described herein and on pages 222 and 223 of the Registration Statement. As discussed below, the methodologies used by AvePoint with the assistance of the third-party valuation firm to determine the fair value of the voting common stock included the market approach (subject company transaction method) and an Option Pricing Model allocation method (“OPM”) to allocate the value of AvePoint. The following table summarizes the valuation dates, methods and resulting valuations used for the accounting for share-based payments in 2020:

Valuation Date

Valuation Methods

Estimated Value per Share of

Voting Common Stock

December 31, 2019

OPM / subject company transaction method

$33.94

August 12, 2020 (retrospective) transaction method / PWERM

$34.32

The assumptions used in each valuation model to determine the fair value of the voting common stock as of the grant date of each option are based on numerous objective and subjective considerations, combined with management judgment, including but not limited to the following:

•

AvePoint’s actual operating results and financial performance;

the prices, preferences, and privileges of shares of AvePoint’s convertible preferred stock relative to shares of AvePoint’s common stock;

current business conditions and projections;

stage of development;

likelihood of achieving a liquidity event, such as an initial public offering or a sale of AvePoint, given prevailing market conditions and the nature and history of AvePoint’s business;

market multiples of comparable companies in AvePoint’s industry;

industry information, such as market size and growth;

secondary sales of AvePoint’s shares in arm’s length transactions;

adjustments, if any, necessary to recognize a lack of marketability for AvePoint’s shares; and macroeconomic conditions.

Determination of Estimated Value

Income

Approach

The income approach attempts to convert future expected economic benefits, generally, cash flow, into a present value. As one application of the income approach, a valuation specialist may utilize the discounted cash flow (“DCF”) method. The DCF method develops a value for a company’s business enterprise as a whole, which is based on direct projections of its future earnings-generating capabilities.

Market Approach

The market approach attempts to value an asset or security by examining observable market values for similar assets or securities. Applications of the market approach may include the guideline company method, back-solve method and subject company transaction method. The guideline company method involves consideration of the market price of stock of comparable public companies and then developing a pricing multiple by dividing the comparable stock’s price by an economic variable. The back-solve method is a method wherein the equity value for a privately-held company is derived from a recent transaction in the company’s own securities. Based on recent transactions, an acceptable model can be used to “back-solve” for the implied equity value of the company. Under the model, the implied equity value is the result of solving such that the implied price of the last round of financing is equal to its issuance price. Similar to the back-solve method, the subject company transaction method is a method wherein a value is derived from a recent transaction in a company’s own securities. However, whereas the OPM back-solve method derives the total 100% equity value, the subject company transaction method derives the value of a share of an individual class of equity. Since the subject company transaction method yields a per share value rather than an aggregate equity value, it is weighted with the result of the OPM allocation (which allocates the total equity value concluded under the other market approach and income approach methods).

Option Pricing Allocation Model

The Black-Scholes OPM can be used to allocate value to the various share classes. The OPM treats securities, including debt and common and preferred stock, as a series of call options on the enterprise’s value, with exercise prices based on the securities’ respective liquidation preferences and conversion values. Accordingly, the common and preferred stock is considered to be a call option with a claim on the enterprise at an exercise price equal to the remaining value immediately after the liquidation preferences are fulfilled, and considering the relevant rights of the preferred stock (e.g., participation) as well as the potential dilution from other outstanding securities such as options and warrants. The OPM considers five key inputs: the total consideration of the most recent transaction, the rights and preferences of the shareholders, time-to-liquidity, the risk-free interest rate, and volatility.

Marketability Discount

In determining the estimated fair value of common stock on the date of grant, it is appropriate to consider that the security may not be freely tradeable in the public markets. The estimated fair value of the voting common stock of AvePoint at each grant date therefore reflects a discount for lack of marketability (“DLOM”), which considers that AvePoint is a closely-held entity with a diversified shareholder base and that the ownership rights of the subject common shares are subordinate to the preferred shares, and is partially based on the anticipated likelihood and timing of a future liquidity event for the subject shares.

Summary of Equity Awards

Since January 1,

2020 and through the date of the initial filing of the Registration Statement, the AvePoint Board has granted the following equity awards, with the share numbers and per share exercise prices and fair values:

Grant Date

Number of

Shares

Underlying

Stock Options

Granted

Exercise

Price

Per Share

Estimated Fair

Value

For Financial

Reporting

Purposes

August 12, 2020

1,327,432

$

33.94

In the absence of a public trading market, the AvePoint Board, with input from management, exercised significant judgment and considered numerous objective and subjective factors to determine the fair value of the common stock as of the date of each option grant, including the factors discussed on pages 222 and 223 of the Registration Statement.

April 28, 3031

December 2019 Financing

On December 26, 2019, AvePoint closed a financing round (the “December 2019 Financing”) in which certain affiliates of TPG Sixth

Street Partners acquired 4,832,409 shares of a newly designated Series C Preferred Stock for a purchase price per share of $31.0404, for a total investment of $150.0 million. In addition, certain investors acquired 657,514 shares of voting common stock of AvePoint for a purchase price per share of $26.3112 for a total investment of $17.3 million, and certain investors invested in AvePoint through an aggregator entity, AVPT, LLC, which acquired 497,735 shares of non-voting common stock for a purchase price per share of $32.889 for a total investment of $16.37 million. The total amount AvePoint raised in the financing was $183.7 million.

AvePoint used the proceeds from the December 2019 Financing to redeem all of the issued and outstanding shares of Series

A-1 Preferred Stock and Series A-2 Preferred Stock for a purchase price per share of $26.3112, and 2,631,842 shares of Series B-1

Preferred Stock and 2,385,032 shares of Series B-2 Preferred Stock for a purchase price per share of $32.889. Following such redemptions, 694,498 shares of Series B-1

Preferred Stock and 351,445 shares of Series B-2 Preferred Stock remained issued and outstanding.

December

2019 Valuation

Following the December 2019 Financing, AvePoint, with the assistance of a third-party valuation firm, performed a valuation of the voting common stock as of December 31, 2019 (the “December 2019 Valuation”). In determining the fair market value of 100% equity of AvePoint, the DCF method under the income approach, and the guideline company method and back-solve method under the market approach were relied upon. In determining the fair market value of the voting common stock, the 100% of equity value was used as an input in the OPM and considered with the subject transaction method.

DCF Method: The DCF model was based on AvePoint management’s projections for revenue and expense, as well as capital expenditure and working capital needs, through December 31, 2027. The projected after-tax cash flows for each year was then discounted back to its present value and added to the present value of the terminal value. The DCF method results in an enterprise value to which AvePoint’s cash balance was added to arrive at a non-controlling, marketable equity value. AvePoint did not have any outstanding debt at the measurement date. The DCF method resulted in an equity value of $712.9 million.

Guideline Company Method: Under the guideline company method, a set of public companies deemed comparable to AvePoint was identified in order to calculate multiples based on the total enterprise value of each of the companies identified in relation to LTM (last twelve months) revenue and NTM (next twelve months) revenue. Based on these data,

AvePoint selected appropriate LTM and NTM multiples to arrive at a total enterprise value for AvePoint, to which its cash balance was added resulting in an estimated non-controlling, marketable equity value. AvePoint did not have any outstanding debt at the measurement date. The guideline company method resulted in an equity value of $731.6 million.

Back-Solve Method: Since AvePoint had a recent financing round prior to the valuation date, the back-solve method was deemed appropriate as a primary valuation methodology. Based on the financing round, the OPM model was utilized to solve for the 100% equity value that yielded a fair market value equal to the issuance price, considering the discounts inherent in the non-voting issuance price. In negotiating a price, it was assumed that the investors in the non-voting stock would consider their lack of voting rights and the lack of marketability in the shares. Given the financing round occurred on December 26, 2019, no adjustment was deemed necessary to carry the value forward to December 31, 2019. Excluding the Series B preferred shares1, AvePoint had an equity value of $730.0 million in such financing.

OPM Allocation Method: After reconciling the results from the DCF method, guideline company method and back-solve method, the concluded 100% equity value for AvePoint, excluding the Series B preferred shares1, was $710.9 million. In order to value the voting common stock, an allocation model was used.

AvePoint intended to and did redeem the Series B Preferred shares (B-1 and B-2) before any liquidation event. Therefore, the fair value of the Series B Preferred was deducted from the aggregate equity value to calculate the aggregate equity value for allocation purposes and the

Series B Preferred shares were excluded from the OPM and Back-Solve Method.

Various allocation methods are acceptable under differing circumstances, including the current value method, probability-weighted expected return method, and OPM. Given the facts and circumstances, AvePoint believed the OPM was the most appropriate allocation model. The aggregate common value allocated on a non-controlling, marketable basis was $370.1 million. The implied per share value for the voting shares of common stock, on a non-controlling, marketable basis after consideration of the voting premium of 5.0%, but before consideration of the DLOM, was deemed to be $37.06 per share.

Subject Company Transaction Method: AvePoint relied on the subject company transaction method to value its voting common stock because there were multiple arms’ length transactions in its common stock around the measurement date. On December 26, 2019, AvePoint issued 497,735 non-voting shares at a price of $32.889 per share, and 657,514 voting shares at a price of $26.3112 per share. The issuance of non-voting shares was deemed more representative of the fair market value on a non-controlling, non-marketable basis, so AvePoint considered the non-voting price to calculate the fair market value of the voting shares using the subject company transaction method. AvePoint used the non-controlling, marketable value of the non-voting common shares sold of $32.889 per share, which assumed a 10% discount (or $3.6543) for lack of marketability and further added a voting premium of 5% (or $1.8272) to conclude an implied fair market value of $38.3705 per voting common share. In determining the DLOM of 10% to be applied to the equity interest value of AvePoint, the fact that AvePoint is a closely held-entity with a diversified shareholder base was considered as was the fact that the ownership rights of the voting common stock are subordinate to the Series B preferred and

Series C preferred shares. Given the issuances occurred on December 26, 2019, no adjustment was deemed necessary to carry the value forward to December 31, 2019.

AvePoint used the per share value of the voting common stock calculated from the OPM allocation method and subject company transaction method. AvePoint gave equal weight to each of the methods to calculate a non-controlling, marketable value of the voting common stock of $37.72 per share. To this non-controlling, but fully marketable equity value, AvePoint applied the 10% marketability discount to yield a fair market value of one share of voting common stock of $33.94.

In

August 2020, the AvePoint Board granted options to purchase 1,327,432 shares of voting common stock with an exercise price of $33.94 per share. In determining the fair value of the voting common stock for the August 2020 grants, the AvePoint Board considered the above valuation and relevant business conditions and, despite the economic uncertainty and headwinds caused by the ongoing COVID-19 pandemic, concluded that the financial forecasts that formed the basis for the valuation were still achievable and therefore AvePoint’s equity value since December 31, 2019 was unchanged.

August 2020

Retrospective Valuation

In January 2021, AvePoint, with the assistance of a third-party valuation firm, performed a retrospective valuation of the voting common stock as of August 12, 2020. This retrospective valuation was prepared using the hybrid model, which used market approaches to estimate AvePoint’s enterprise value. The hybrid model is a probability-weighted expected return model (“PWERM”), sometimes referred to as a scenario-based model, where the equity value in one or more scenarios is calculated using the OPM method and other scenarios may consider alternative allocation methods. The two scenarios considered as part of the PWERM were a Merger and Acquisition (“M&A”) scenario and an Initial Public Offering (“IPO”) scenario, which were probability weighted at 99% and 1%, respectively.

In the M&A scenario, AvePoint used the per share value of the voting common stock calculated from the OPM allocation method and subject company transaction method. The concluded equity value for AvePoint, used in the OPM was $753.0 million. The aggregate common value allocated on a non-controlling, marketable basis was

$399.2 million. The implied per share value for the voting shares of common stock, on a non-controlling, marketable basis after consideration of the voting premium of 5.0%, but before consideration of the

DLOM, was deemed to be $37.38 per share.

The subject company transaction method was also used to value its voting shares of common stock because there were transactions around the valuation date. On June 19, 2020, AvePoint issued 722,734 non-voting shares at the price of $32.889 per share. AvePoint used the non-controlling, marketable value of the non-voting common shares sold of $32.889 per share, which assumed a 10% discount (or $3.6543) for lack of marketability and further added a voting premium of 5% (or $1.8272) to conclude an implied fair market value of $38.3705 per voting common share. The OPM and subject company method fair market values were equally weighted at 50% to arrive at a fair value of $37.88 to which a 10% DLOM was applied to arrive at a fair market value of $34.09 per share.

In the IPO scenario, the concluded equity value for AvePoint was $1.3 billion based upon management’s estimate. The expected value at the IPO was allocated to the classes of equity using the Current Value Method, also known as the Waterfall Method, then discounted back to the measurement date to derive a present value. The aggregate common value allocated on a non-controlling, marketable basis was $746.2 million. The implied per share value for the voting shares of common stock, on a non-controlling, marketable basis was deemed to be $57.38 per share. The IPO scenario did not consider a non-voting discount or a DLOM, assuming all shares participate in the same manner under the IPO scenario.

Applying the scenario probability weighting of 99% and 1%, respectively, resulted in a concluded fair market value of voting common stock of $34.32 per share.

AvePoint considered that the retrospective valuation as of August 12, 2020, reflected a higher price per share of $0.38 per share relative to the valuation as of December 31, 2019, and concluded that even if such fair market value was appropriate, after calculating the Black-Scholes value of such difference across the aggregate number of shares underlying such options, the incremental stock-based compensation expense was immaterial to any period.

Business Combination Agreement

On November 23, 2020, the Company and AvePoint announced the proposed business combination of the companies which had a concluded equity value for

AvePoint of $1.99 billion. The implied fair value of the shares of AvePoint common stock as determined by the exchange ratio in the business combination is $86.85 per share. The Company respectfully submits that the increase in equity value from the August 2020 grant date to the date of the business combination agreement is attributable to several factors, as discussed below:

Commencing in March 2020 and continuing into the third quarter of 2020, AvePoint experienced significant apprehension from customers on IT-related spending projects due to significant global economic uncertainty as a result of the ongoing COVID-19 pandemic. In the second quarter of 2020, AvePoint responded by reducing its work force by approximately 10% in anticipation of an economic slow-down.

During the first nine months of 2020, AvePoint’s financial results and trends reflected the economic uncertainties facing technology concerns:

On a GAAP basis, AvePoint’s revenue was $32.7 million, $39.9 million and $39.8 million during the three months ended March 31, June 30 and September 30, 2020, respectively.

On a Non-GAAP basis, AvePoint’s operating income was only approximately $5,000 during the three months ended March 31, 2020, and increased to $4.8 million and $6.8 million during the three months ended June 30 and September 30, 2020, respectively.

Total ARR (as discussed on page 202 of the Registration Statement) was $97 million, $104 million and

$112 million during the three months ended March 31, June 30 and September 30, 2020, respectively.

AvePoint’s other key business metrics (as discussed on pages 202 and 203) of the Registration Statement) reflected similar fluctuations and trends.

In September 2020, in light of an improving business outlook, but cognizant of business conditions which existed at the outset of the COVID-19 pandemic earlier in the year, and its June 2020 financing which did not reflect any increase in value from the December 2019 financing, AvePoint approached existing investors regarding a potential financing valuing AvePoint at $1 billion ($53.40 per share). On September 28, 2020, certain existing AvePoint investors acquired 676,525 shares of non-voting common stock at a purchase price of $53.40 per share, for aggregate gross proceeds of $36.1 million.

Although AvePoint had experienced a significant amount of uncertainty commencing in March 2020 and continuing into the third quarter of 2020, in September 2020, macroeconomic factors began changing. Per the BEA, U.S. GDP improved 33.4% in the third quarter as compared to the second quarter. AvePoint customers began to re-start conversations, and confirm and expand software orders as the economy appeared to be accelerating/shifting a trend toward a technologically focused environment, heavily attributable to labor-force dynamics necessitating a rapid increase in remote work. As an example, Microsoft, one of the core platforms for AvePoint’s solutions, announced a growth in daily active Teams users exceeding 50% in just five months, from 75 million in May

2020 to 115 million in October 2020.

As sales orders solidified through the third quarter 2020, AvePoint re-forecasted its 2020, 2021 and 2022 revenue, gross profit and EBIT (each as disclosed on page 103 of the Registration Statement), which reflect significant increases from the financial forecasts available to the AvePoint Board at the time of the December 2019 Valuation and used to determine to the fair value of the common stock in August 2020.

The S&P 500, Dow Jones Industrial Average, Nasdaq and broad market Wilshire 500 indices posted broad gains in the third quarter of 2020 on steadily improving economic data and surges in large technology stocks. Improved consumer spending and hiring data, which were both up in the third quarter of 2020, boosted investor confidence, leading to the widespread gains seen in major equity indices during the third quarter.

AvePoint’s peer companies began experiencing significant growth and publicly-traded SaaS companies traded at all-time high multiples, per the SaaS Capital Index, closing the third quarter 2020 at north of 14x revenue multiples. The equity market was further buoyed by significant SaaS IPOs, such as Snowflake, JAMF,

JFrog, and Sumo Logic. During September 2020, seven SaaS companies completed IPOs, equaling the total IPOs during the June to August 2020 period.

As the realization of COVID’s impact on the transformation of the digital workplace came to the forefront,

SaaS company valuations continued to rise, with the monthly SaaS Capital Index rising from 15.0x next twelve months (NTM) revenue as of September 30, 2020 to 15.8X NTM of November 30, 2020.

Summary

The Company believes that the sales to third parties of AvePoint’s securities reflect the uncertainty of 2020 and the impact of the COVID-19 pandemic on AvePoint’s business, and as evidenced by the price per share AvePoint was able to negotiate for its non-voting shares of common stock on December 26, 2019 ($32.889 per share), June 19 , 2020 ($32.89 per share) and September 28, 2020 ($53.40 per share).

The Company respectfully submits that the AvePoint Board’s determination of the fair value of its voting common stock for financial reporting purposes is appropriate in light of the economic uncertainty caused by the COVID-19 pandemic and its initial impact on AvePoint during the first part of 2020, and the subsequent increase in equity value in the latter part of 2020 is a reflection of the continued acceleration of market adoption of AvePoint’s software solutions designed to enable its customers’ work from anywhere initiatives coupled with expanding revenue multiples across AvePoint’s SaaS peer group.

* * *

If you have additional questions or require any additional information with respect to the

Revised Registration Statement or this letter, please do not hesitate to contact me at [email protected] or (650) 463-4662.

Read in the reply
General
SEC asked (4)
You announced that AvePoint’s Board of Directors has authorized a share purchase program pursuant to which AvePoint may purchase up to $20.0 million of Apex Technology Acquisition Corporation common stock until the date on which Apex’s S-4 Registration Statement is declared effective. In addition, you disclosed that a PIPE transaction will also be conducted in connection with the business combination.
Rest of the question

Please provide us with the details of the share purchase program. Provide an analysis for the following: • Explain how such purchases would comply with the requirements of Rule 14e-5 under the Exchange Act. Ensure your analysis includes a discussion of whether you are a "covered person" pursuant to Rule 14e-5(c)(3)(iv); and • Explain how you intend to conduct such purchases/transactions so as to comply with the trading prohibitions of Rules 101 and 102 under the Exchange Act. Ensure your analysis includes, among other things, a discussion of how you calculate the applicable “restricted periods” pursuant to Rule 100 of Regulation M for both the de- SPAC/merger distribution, as well as the PIPE distribution. Also, please clarify and confirm whether you intend to rely on the safe harbor protection under Rule 10b-18 in making the open market purchases and, if so, please explain to us how you intend to structure such purchases so as to comply with the specific provisions of the safe harbor in Rule 10b-18, particularly the “merger exclusion” provision in paragraph (a)(13)(iv).

AVPT answered

No numbered answer found in the reply. Read the reply ↗

Critical Accounting Policies and Estimates · Equity-Based Compensation, page 222
SEC asked
We note your letter dated April 28, 2021 and we request additional analysis supporting your estimated fair value of shares of the Company's common shares. Please tell us how you considered the September 2020 financing arrangement that valued non-voting common stock at a purchase price of $53.40 per share as it relates to the retrospective estimated fair value per voting common stock of $34.32 on August 12, 2020.
Rest of the question

Provide the factors that resulted in this significant increase over a short period of time. Explain in greater detail why your valuation remained flat for the first eight months of the year then spiking in September and November while revenue appears to have been consistent throughout 2020. Your fourth quarter revenue for 2020 appears to have been in line with the earlier quarters of 2020 and does not present a similar spiking that your valuation reports. Further, please contrast your bullet point regarding how COVID-19 affected your operations as described in your response letter to the disclosures on page 201 of your MD&A. For example, you disclose that "AvePoint has not experienced any material negative impacts" and "despite global headwinds and market volatility, during the year ending December 31, 2020 AvePoint experienced a 31% increase in revenue." These factors suggest that your valuation would be increasing over this period of time of instead of remaining flat and then spiking. Please advise. In addition, please quantify the impact of each factor that you list to support the difference between the August 12, 2020 valuation and November 23, 2020, the date of the announced proposed business combination.

AVPT answered
Summary

On August 12,

2020, the board of directors of AvePoint, Inc. (“AvePoint” and the “AvePoint Board”), granted stock options to purchase 1,235,891 shares of common stock with an exercise price of $33.94 per share (the

“August Grant Date”). In determining the exercise price, the AvePoint Board considered the factors as set forth on page 176 of the Revised Registration Statement, as well as a contemporaneous third-party valuation report as of December 31, 2019 (the “December 2019 Valuation”) and a sale of common stock to non-affiliated third parties in arm’s-length transactions in June
Rest of the answer

2020. Subsequent to December 31, 2020, AvePoint management performed a retrospective valuation as of the August Grant Date, which further supported the AvePoint Board’s prior determination of fair value per share as of such date.

The Company respectfully submits that AvePoint’s valuation is driven primarily by changes in: (i) revenue and

(ii) valuation multiples, and is validated by sales of capital stock to non-affiliated third parties in arm’s-length transactions. As discussed below, the primary difference in per share value between the August Grant Date of $33.94 and the implied fair value of $86.85 as determined by the exchange ratio in the proposed business combination is the change in next

12-month (“NTM”) revenue and AvePoint’s selected revenue multiple.

The Company respectfully submits that the decision of the AvePoint Board to rely on the December 2019 Valuation, in light of the effect of the ongoing COVID-19 pandemic on its business and sales of its common stock within the preceding 60 days of the August Grant Date, was appropriate and represents the fair value of its common stock on such date, based upon all information available to the AvePoint Board on such date, as discussed in further detail below.

Retrospective Valuations

In addition to the December 2019 Valuation, AvePoint performed retrospective valuations as of June 30, 2020,

August 12, 2020 and September 30, 2020. The following table summarizes the valuation dates, methods and resulting valuations:

Valuation Date

Valuation Methods

Estimated Value per Share of

Voting Common Stock

December 31, 2019

OPM / subject company transaction method

$33.94

June 30, 2020

(retrospective)

$33.86

August 12, 2020 transaction method /

PWERM

$34.32

September 30, 2020

$55.61

The assumptions used in each valuation model to determine the fair value of the voting common stock as of a particular date are based on numerous objective and subjective considerations, combined with management judgment, including but not limited to the following:

•

AvePoint’s actual operating results and financial performance;

the prices, preferences and privileges of shares of AvePoint’s convertible preferred stock relative to shares of AvePoint’s common stock;

current business conditions and projections;

stage of development;

likelihood of achieving a liquidity event, such as an initial public offering or a sale of AvePoint, given prevailing market conditions and the nature and history of AvePoint’s business;

market multiples of comparable companies in AvePoint’s industry;

industry information such as market size and growth;

secondary sales of AvePoint’s shares in arm’s-length transactions;

adjustments, if any, necessary to recognize a lack of marketability for AvePoint’s shares; and macroeconomic conditions.

The below table summarizes the primary key analytical factors utilized in such valuations that AvePoint believes drove the increase in value of its common stock in 2020. These factors are discussed below in greater detail.

December 31,

2019

June 30,

2020

August 12,

September 30,

LTM Revenue(1)

$117.2 mm

$131.9 mm

$141.6 mm

NTM Revenue(2)

$135.1 mm

$164.5 mm(3)

$171.0 mm(4)

$184.3 mm(5)

LTM Revenue Multiple

6.0x

5.4x

NTM Revenue Multiple

4.9x

Time to a Liquidity Event

1.5 years

1.0 years

0.89 years

0.42 years

DCF Equity Value

$712.9 mm

$678.2 mm

$660 mm

$968.3 mm

Fair Value Per Share

$33.86(6)

$55.61(7)

(1)

Last 12-month (“LTM”) revenue

(2)

Next 12-month (“NTM”) revenue

(3)

Retrospectively calculated as approximately 50% x 2020E revenue plus 50% x 2021E revenue

(4)

Retrospectively calculated as approximately 62.5% x 2020E revenue plus 37.5% x 2021E revenue

(5)

Retrospectively calculated as approximately 75% x 2020E revenue plus 25% x 2021E revenue

(6)

On June 19, 2020, AvePoint sold 722,697 shares of non-voting common stock to third-party investors at a purchase price of $32.889 for aggregate proceeds of $23.8 million.

(7)

On September 28, 2020, AvePoint sold 676,525 total shares of common stock to third-party investors at a purchase price of $53.40 per share for aggregate proceeds of $36.1 million.

A. Please tell us how you considered the September

2020 financing arrangement that valued non-voting common stock at a purchase price of $53.40 per share as it relates to the retrospective estimated fair value per voting common stock of $34.32 on

August 12, 2020. Provide the factors that resulted in this significant increase over a short period of time. Explain in greater detail why your valuation remained flat for the first eight months of the year then spiking in September and November while revenue appears to have been consistent throughout 2020. Your fourth quarter revenue for 2020 appears to have been in line with the earlier quarters of 2020 and does not present a similar spiking that your valuation reports.

Response:

The Company respectfully advises the Staff that the retrospective valuation performed in January 2021, which re-calculated the value of AvePoint common stock as of August 12, 2020, did not explicitly utilize in the subject company method the September 2020 financing arrangement (the “September 2020

Financing”) in which 676,525 shares of non-voting common stock were issued a purchase price of $53.40 per share, as the September 2020 Financing was not known as of August 12,

2020. AvePoint utilized the June 2020 Financing for purposes of the subject company transaction method, but did retrospectively adjust its forecasted NTM revenue for the OPM method, as AvePoint believed that the retrospective adjustment of its forecast was appropriate for the application of the valuation methodology and therefore did give weight to the improving revenue forecast that was considered by the investors in the September 2020 Financing. As discussed in the

Prior Response Letter, the OPM and subject company method fair market values were equally weighted at 50% to arrive at a fair value of $37.88 to which a 10% discount for lack of marketability was applied to arrive at a fair value of $34.09 per share. This input was subsequently used in the PWERM to arrive at the ultimate fair value of $34.32 per share as of August 12, 2020.

AvePoint believes that the following factors contributed to the increase in fair market value of its common stock from $33.94 per share as of

December 31, 2019 through the August Grant Date to $53.40 per share in the September 2020 Financing utilizing a consistent valuation methodology:

Revenue

AvePoint’s revenues for the relevant quarterly periods was as follows:

Three Months Ended

Revenues

Sequential Change from

Prior Quarter

$35.1 million

—

March 31, 2020

$32.7 million

(7.0)%

June 30, 2020(1)

$33.0 million

0.9%

$39.8 million

20.8%

December 31, 2020

$46.1 million

15.9%

The Company respectfully advises the Staff that there was an error in the Prior Response Letter which stated that AvePoint’s revenue for the second quarter of 2020 was $39.9 million, when revenue for this period was actually $33.0 million.

The Company respectfully advises the Staff that AvePoint’s revenues for the three months ended December 31, March 31 and

June 30 and the first two months of the third quarter was flat. AvePoint’s revenue declined 7.0% from the fourth quarter of 2019 to the first quarter of 2020, as COVID-19 began impacting demand for

AvePoint’s products. AvePoint’s quarterly revenue was flat at $32.7 million and $33.0 million in the first and second quarters of 2020, respectively. AvePoint continued to experience flat revenue for July and August 2020, as revenue for each of these two months was only approximately 2.2% greater than the respective month of the second quarter. As of the August Grant Date, all available revenue data suggested that revenues for the third quarter would be flat and consistent with the first and second quarters of 2020.

The Company respectfully submits that it was not until September 2020 that

AvePoint began to see an inflection in its revenue data, as over 50% of AvePoint’s revenue for the third quarter 2020 was recognized in September 2020. By the time of the September 2020 Financing, AvePoint had greater insight into its revenue data for the third quarter of 2020, and its revenue for September 2020 was 46% higher than AvePoint’s monthly revenue in June 2020, in part due to the fact that AvePoint received higher than typical on-premise license and service revenue, particularly from certain the U.S. federal government agencies as they approached their fiscal year end. This quarterly seasonality was disclosed within AvePoint’s

MD&A section on page 168 of the Revised Registration Statement.

The following is a month-by-month revenue comparison of AvePoint’s second and third quarters:

Second

Quarter

Third Quarter

Period-over-

Period

Cumulative

Month 1

$

8.8 million

9.3 million

6.7

%

Month 2

10.4 million

10.2 million

(1.5

)%

2.2

Month 3

13.8 million

20.2 million

46.4

20.8

Total

33.0 million

39.8 million

AvePoint saw continued sequential growth in the fourth quarter with 15.9% revenue growth. This growth was fueled by strong sales growth in the third and fourth quarters as customers invested in solutions to facilitate remote work caused by COVID-19. This is consistent with AvePoint’s historical sales, in that the third quarter is the budgetary year end for public sector agencies while the fourth quarter is aligned with most commercial budgetary cycles. AvePoint saw strong demand for early renewals of on-premises solutions with companies looking to utilize budgets prior to the end of their fiscal year on December 31, 2020.

Valuation Multiples

The median revenue multiples of AvePoint’s guideline public companies (“GPC”) for valuation purposes were:

Median LTM Multiple

Median NTM Multiple

6.93x

6.25x

6.36x

6.21x

6.38x

5.70x

6.76x

5.87x

The growth in valuation multiples helps to quantify more qualitative inputs related to the larger macroeconomic environment and investor views of the technology sector, specifically as it relates to publicly traded SaaS companies. The median multiples slightly declined from December 31, 2019 to June 30, 2020, supporting AvePoint’s flat valuation as of June 30, 2020. GPC multiples increased from June 30, 2020 through the end of the year. AvePoint’s peer companies for purposes of the GPC multiples did not change during 2020.

Due to economic uncertainties, AvePoint reduced its selected revenue multiples from December 31, 2019 to June 30, 2020. Such uncertainties were largely related to COVID-19 during the first eight months of 2020. COVID-19 was in full force during this time and, in AvePoint’s first quarter, customers began expressing concern and uncertainty about their future IT spending, especially in industry sectors where COVID-19 appeared to have more substantial effect, including but not limited to hospitality, airline, travel and leisure. It was not until September 2020 that AvePoint’s revenue began growing significantly, and so for the September 30, 2020 valuation AvePoint raised its revenue multiples back to its selected

December 31, 2019 multiples.

AvePoint’s selected revenue multiples for valuation purposes were:

Selected LTM Multiple

Selected NTM Multiple

During the first eight months of 2020, AvePoint considered the possibility of a liquidity event to be almost non-existent. Sales were flat, customers were pulling back their IT-related spending, AvePoint had reduced its work force by approximately 10%, and AvePoint had applied and received approval for (but ultimately rejected) a PPP loan. For the December 2019 Valuation, the time to a liquidity event was estimated at 1.5 years. This time decreased as

AvePoint moved through 2020 to 0.42 years (or approximately five months as of the September 30, 2020 valuation). With the benefit of hindsight, the time to liquidity events estimated by

AvePoint and utilized in the valuations in 2020 should have assumed longer time horizons, given the parties do not expect to close the business combination until July 2021 (which is approximately 1.5 years from December 31, 2019).

Based in part on demand in the September 2020 Financing, the purchase price per share in the September 2020 Financing and increased public markets activity in the SaaS industry as a whole, AvePoint began internally contemplating a potential initial public offering. However, as of the August Grant Date, AvePoint had not engaged any professional related to a potential initial public offering and had not mandated any investment bank. As set forth in the Revised Registration Statement, on August 26, 2020, AvePoint began preliminary discussions with the Company concerning a potential business combination.

Sales of Securities to Non-Affiliated Third Parties

The AvePoint Board’s decision to use the price of $32.889 per share, as determined by the December 2019 Valuation, was further supported by AvePoint’s recent common stock financing which raised $23.8 million from 20 investors at $32.889 per non-voting common share at June 19, 2020 (the “June 2020

Financing”). The non-voting common shares were only non-voting because of regulations related to CFIUS and upon any public transaction, the non-voting common shares will convert to voting common shares. Beyond that distinction, there is no difference between the voting and non-voting common shares and AvePoint believes they should be viewed from a valuation standpoint as the same or substantially the same. These investors were all non-affiliated third parties.

Qualitative Factors

In addition to the quantitative factors, there are several qualitative factors that contribute to the valuation of AvePoint as of the August Grant Date, which had changed significantly by the end of September 2020. Specifically, AvePoint reduced its work force by approximately 10% between June and July 2020. AvePoint also applied and was awarded but ultimately rejected a PPP loan in June 2020. At that time and based on conversations with its customers, AvePoint anticipated that its customers would begin suspending IT spending, especially in industry sectors where COVID-19 appeared to have more substantial effect, including but not limited to airline, travel and leisure. However, in September 2020, it became clearer that with people largely working from home and relying on Microsoft technologies to enhance collaboration, AvePoint would begin to see an uptick in revenue, as companies began to invest significantly more in Microsoft and

Microsoft-related technologies, as evidenced by an increase from approximately 32 million daily active Microsoft Team users at the beginning of March 2020 to 115 million by the end of October 2020.

The aforementioned company-specific attributes and industry factors, as evidenced by increasing GPC multiples, SaaS IPO activity and increases in broad sector indices, such as the Bessemer Cloud Index (EMCLOUD), as well as the qualitative reasons set forth above, supported an increased purchase price in the September 2020 Financing.

B. Further, please contrast your bullet point regarding how COVID-19 affected your operations as described in your response letter to the disclosures on page 201 of your MD&A. For example, you disclose that “AvePoint has not experienced any material negative impacts” and “despite global headwinds and market volatility, during the year ending

December 31, 2020 AvePoint experienced a 31% increase in revenue.” These factors suggest that your valuation would be increasing over this period of time of instead of remaining flat and then spiking. Please advise.

Response:

AvePoint’s commentary in its Management’s Discussion and Analysis of Financial Condition and Results of Operation included in the Revised Registration Statement (“AvePoint’s MD&A”) reflects AvePoint management’s view of the impact of COVID-19 on AvePoint’s business as of December 31, 2020. At December 31, 2020, AvePoint management had greater insight into the effects of COVID-19 than it did as of the August Grant Date and at the time of the September 2020 Financing. Prior to the August Grant Date, there was significant uncertainty associated with COVID-19 which posed risk to

AvePoint’s operations and management acted accordingly, including by reducing its workforce by approximately 10% and having been approved for a PPP loan (which it ultimately declined to take).

Despite this, as noted in AvePoint’s MD&A, revenue in 2020 increased 31% from 2019. Nearly all of the increase in revenue occurred in September 2020 and the fourth quarter of 2020. The higher per share purchase price in the September 2020 Financing reflects the observed increase in revenue in September 2020, greater insight into the full-year impact of COVID-19 on AvePoint’s business, and improving macroeconomic conditions.

C. In addition, please quantify the impact of each factor that you list to support the difference between the

August 12, 2020 valuation and November 23, 2020, the date of the announced proposed business combination.

Response:

On November 23, 2020, the Company and AvePoint announced the proposed business combination of the companies which had a concluded equity value for AvePoint of $1.99 billion. The implied fair value of the shares of AvePoint common stock as determined by the exchange ratio in the business combination is $86.85 per share.

As disclosed in AvePoint’s investor presentation filed by the Company on a Current Report on Form

8-K on November 23, 2020, AvePoint estimated $193.1 million in 2021 revenues and was afforded a 9.0x NTM revenue multiple resulting in a pro forma equity value of approximately $1,738 million in the proposed business combination.

As of the August Grant Date, the AvePoint Board had for its consideration the December 2019 Valuation, which estimated 2020 revenues to be approximately $135.1 million, an increase of $18.1 million from 2019 actual revenue of $117.0 million, representing 15% growth. This valuation afforded AvePoint a 5.4x NTM revenue multiple (which was slightly below the median NTM multiple of AvePoint’s peer group of 6.25x). The resulting unadjusted pro forma equity value was approximately $730.0 million.

The retrospective valuation performed as of August 12, 2020, estimated NTM revenues to be approximately $171.0 million and used a

NTM multiple of 4.9x (which was slightly below the median NTM multiple of AvePoint’s peer group of 5.7x). The resulting unadjusted pro forma equity value was $837.9 million.

The below table illustrates how the increase in NTM revenue coupled with the increase in NTM revenue multiple increased the pro forma equity value by approximately $1.0 billion between December 31, 2019 (the valuation date used for the August Grant) and the announcement of the proposed business combination on November 23, 2020. While simplistic in its analysis, the Company respectfully submits the below is an “apples-to-apples” comparison of the relevant factors. While the valuations of AvePoint’s common stock for financial reporting purposes were determined in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as

Compensation (the “Guide”), the Company’s determination of fair value per share in connection with the proposed business combination was based on revenues and a revenue multiple.

November 23,

NTM Revenue

135.1 mm

171.0 mm

193.1 mm

9.0x

Pro Forma Equity Value(1)

730.0 mm

837.9 mm

1,738 mm

33.94

34.32

86.85

Pro forma equity value has not been adjusted for any voting control premiums or discounts for lack of marketability and simply represents NTM Revenue multiplied by the afforded NTM Revenue Multiple.

As discussed in the Prior Response Letter, Fair Value Per Share as of December 31, 2019 and August 12,

2020 is adjusted for a voting control premium and discount for lack of marketability in accordance with the Guide.

The

Company respectfully submits that the decision of the AvePoint Board to rely on the December 2019 Valuation in light of the effect of the ongoing COVID-19 pandemic on its business, and precedent sales of its common stock within the preceding 60 days of the August Grant Date, was appropriate and represents the fair value of its common stock on such date, based upon all information available to the AvePoint Board on such date as discussed above. In addition, the fair value is supported by the retrospective valuation performed as of August 12, 2020, which did retrospectively take into account higher forecasted revenues in 2021.

* * *

If you have additional questions or require any additional information with respect to the

Revised Registration Statement or this letter, please do not hesitate to contact me at [email protected] or (650) 463-4662.

Read in the reply

Also in this review: company letter, May 19, 2021, company letter, May 28, 2021, company letter, Jun 1, 2021, company letter, Aug 5, 2021

Form S-1

2019-08-12 to 2019-09-12 · 3 questions · 2 letters from the SEC, 4 from the company
No closing letter
Draft Registration Statement on Form S-1 submitted July 16, 2019 · Our Company, page 2
SEC asked (1)
Please revise to explain the bases upon which Kyriba, Uber, and Slack "have rewarded their stockholders handsomely" and the source of your information. We also note that Kyriba is a private company, so the basis for this statement is particularly unclear. Please also indicate what impact, if any, the successes of these companies would have on your proposed business operations.
AVPT answered
to the Staff’s comment, we have removed the disclosure below:

“An array of visionary private technology companies, such as Kyriba, Uber and Slack that drove these changes, also remodeled industries and scaled rapidly to become household names. They, in turn, rewarded their stockholders handsomely.”
Read in the reply
General
SEC asked (2)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
AVPT answered
to the Staff’s comment, we will provide all such written communications under separate cover. We confirm that potential investors will not retain copies of any such communications.

* * *

We thank the Staff in advance for its consideration of the foregoing. Should you have any questions, please do not hesitate to contact our legal counsel, Stuart Neuhauser, Esq., of Ellenoff Grossman & Schole LLP, at (212) 370-1300.
Read in the reply
Exhibits
SEC asked
We note that Section 9.3 of your Warrant Agreement, filed as Exhibit 4.4, is to be governed by New York law. Please have counsel revise the legal opinion filed as Exhibit 5.1 to include New York law, as it relates to the binding obligations of the company under the Warrant Agreement.
AVPT answered
to the Staff’s comment, counsel has revised Exhibit 5.1 to include the required language.

* * *

We thank the Staff in advance for its consideration of the foregoing. Should you have any questions, please do not hesitate to contact our legal counsel,

Stuart Neuhauser, Esq., of Ellenoff Grossman & Schole LLP, at (212) 370-1300.
Read in the reply

Also in this review: company letter, Sep 12, 2019, company letter, Sep 12, 2019

Letters without questions

Other letters

UPLOAD and CORRESP
1 other letter: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 24 letters filed since 2019-08-13. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AVPT/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.